- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Julie Reed Previews 2022: The Year of Expanded Access to Biosimilars
As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
Transcript:
If 2020 was the year of the BPCIA [Biologics Price Competition and Innovation Act] rule change, and 2021 was the year of the first interchangeable biosimilar, and 2023 is going to be the year of adalimumab biosimilars, what milestone do you hope to see happen in 2022?
Access. We want to see the government deliver proactive incentive policies and increase access and uptake. We want to see payers improve their processes to include more biosimilars or all biosimilars on their formularies, not just one. We want to see BsUFA [Biosimilar User Fee Amendments of 2017], a robust FDA resourced biosimilars program, done. We want to see misinformation stopped before it goes out. We want to see HHS follow up on the president's executive order. We want to see the puzzle put together and the foundation that we need to capture all those savings. We want to lay all of that this year. It's time.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD
October 30th 2024Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).
Read More
